Evox Therapeutics Ltd, an exosome therapeutics company, has appointed Dr. Per Lundin, Co-Founder and Chief Business Officer, as Chief Executive Officer (CEO) of the Company and a member of its Board of Directors.
 
Following more than six years with the Company, Dr. Antonin “Tony” de Fougerolles has decided to step down as CEO and Director of Evox. Tony will continue to support the Company as a strategic adviser.

About Dr. Per Lundin

Lundin has more than 15 years’ experience founding, leading, and advising biotech companies developing advanced therapies, including co-founding Evox in 2016. Prior to Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and prior to that worked in business development and as an IP attorney in a leading European law firm.
 
Lundin serves as non-executive director of publicly listed gene therapy company Combigene and research committee member and board director of JDRF International and JDRF UK, respectively. He is a qualified European Patent Attorney with extensive leadership, business development and operational experience; he earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business.
 
Lundin worked closely with Tony over the last six and a half years to significantly progress the business.
 
“I have enjoyed working closely with Tony over the years and I look forward to leading the Company as we advance our cutting-edge technology, DeliverEX, to accelerate the development of exosome-enabled genetic medicines,” Lundin remarked.